President, Clinical Next Generation Sequencing, Thermo Fisher Scientific
BIOGRAPHY
APR 29, 2021 12:25 PM PDT
Current and upcoming pharma collaboration and IVD strategy
Presented at:
OncomineWorld 2022: A Virtual NGS Education Meeting
Speaker
Abstract
Thermo Fisher Scientific have spearheaded the development and democratization of next-generation sequencing, a technology that has fueled research in precision oncology and will play a key part in its broad implementation for patients. Dr. Garret Hampton, president of the Clinical Sequencing Division will talk current and future Oncomine IVD and companion diagnostics (CDx) solutions and namely about plans for IVD submissions of future Oncomine Dx Express Test on Genexus System.
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
Loading Comments...